Key result
Nonalcoholic fatty liver disease was associated with a significantly higher risk of atrial fibrillation (RR 1.42; 95% CI 1.19-1.68; p<0.001), heart failure, stroke, and cardiovascular mortality.
Why the study?
The association between nonalcoholic fatty liver disease and cardiovascular and cerebrovascular outcomes, as well as their clinical impact, had yet to be established.
Does nonalcoholic fatty liver disease (NAFLD) increase the risk of atrial fibrillation, heart failure, stroke, cardiovascular mortality, and revascularization compared to non-NAFLD patients?
Population
18,055,072 patients across 12 cohort studies
Comparison
NAFLD vs non-NAFLD
Design
Meta-analysis of cohort studies
Follow-up
Mean 6.26 years
Authors
Loading...
May warrant enhanced CV surveillance in NAFLD; leaves open whether NAFLD treatment reduces AF, HF, stroke, or mortality.
Meta-Analysis (n=18,055,072)
Does nonalcoholic fatty liver disease (NAFLD) increase the risk of atrial fibrillation, heart failure, stroke, cardiovascular mortality, and revascularization compared to non-NAFLD patients?
Relative Risk: 1.42 (95% CI 1.19–1.68)
p-value: p=< 0.001
NAFLD is significantly associated with an increased risk of atrial fibrillation, heart failure, stroke, revascularization, and cardiovascular mortality.
Jaiswal et al. (2023) conducted a meta-analysis in Nonalcoholic fatty liver disease (NAFLD) (n=18,055,072). Nonalcoholic fatty liver disease (NAFLD) vs. Non-NAFLD was evaluated on Atrial fibrillation (AF) (RR 1.42, 95% CI 1.19, 1.68, p=< 0.001). Nonalcoholic fatty liver disease was associated with a significantly higher risk of atrial fibrillation (RR 1.42; 95% CI 1.19-1.68; p<0.001), heart failure, stroke, and cardiovascular mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: